To assess resource use, costs and clinical outcomes among COPD patients who initiate therapy with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol
Latest Information Update: 22 Jul 2022
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
Most Recent Events
- 22 Jul 2022 New trial record